Providence Ventures generally targets mid- to late-stage venture investments across Healthcare IT, MedTech, and tech-enabled services.
Business Model:
Revenue: $3M
Employees: 2-10
Address: 800 5th Ave Ste 10
City: Seattle
State: WA
Zip: 98104
Country: US
Providence Ventures generally targets mid-to late-stage venture investments across Healthcare IT, MedTech, and tech-enabled services. Over the life of an investment, they seek to deploy $8 to $15 million. Their best opportunities to add value are investments that align the interests of their portfolio companies and the innovation priorities of Providence Health &a; Services, through broad solution deployment and strategic insight. The innovation opportunities PHS targets as a large health system tend to reflect the priorities of the US health system overall. They welcome the opportunity to partner with established venture funds as co-investors, however, syndication is not a prerequisite for their participation. Providence Ventures is founded in 2014 which manages $300 million in venture capital funds on behalf of Providence St. Joseph Health (PSJH), one of the largest integrated health systems in the US. The company&s;s mission is to achieve venture and growth equity class returns through direct investments in innovative healthcare companies that improve health outcomes, lower costs, and enhance the experience of our patients and caregivers. It offers investment capital, combined with health system expertise, to companies addressing existing and emerging pain points in healthcare. Providence Ventures partners with our portfolio companies to refine existing solutions, while expanding their adoption within and beyond our health system.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
8/2019 | Protenus | Series C | 0 |
9/2021 | Xealth | Series B | 0 |
6/2021 | TailorMed | Venture Round | 0 |
1/2019 | Bolder Surgical | Series C | 27M |
6/2019 | Omada Health | Series D | 73M |
7/2021 | Kno2 | Series A | 0 |
3/2016 | Gauss Surgical | Series B | 0 |
3/2020 | Lyra Health | Series C | 0 |
1/2020 | Kyruus | Series D | 42M |
8/2020 | Lyra Health | Series D | 110M |
7/2016 | N-of-One | Series B | 7M |
2/2021 | SpineZone | Series A | 12M |
3/2022 | Wildflower Health | Venture Round | 0 |
3/2019 | Xealth | Series A | 0 |
4/2018 | Kyruus | Corporate Round | 0 |
4/2022 | impact.com | Private Equity Round | 0 |
3/2021 | DexCare | Series A | 0 |
6/2017 | Intelligent Retinal Imaging Systems | Series B | 9M |
1/2022 | DexCare | Series B | 0 |
3/2016 | Sqord | Seed Round | 1M |
11/2017 | Collective Medical Technologies | Series A | 47.5M |
1/2015 | Sqord | Venture Round | 0 |
2/2020 | Twistle | Venture Round | 18M |
5/2015 | InDemand Interpreting | Venture Round | 0 |
12/2016 | Bona Film Group | Private Equity Round | 0 |
6/2021 | Protenus | Series D | 0 |
6/2021 | Arrive Health (formerly RxRevu) | Funding Round | 0 |
5/2018 | Lyra Health | Series B | 0 |
4/2022 | impact.com | Private Equity Round | 0 |
3/2022 | Wildflower Health | Venture Round | 0 |
1/2022 | DexCare | Series B | 0 |
9/2021 | Xealth | Series B | 0 |
7/2021 | Kno2 | Series A | 0 |
6/2021 | Arrive Health (formerly RxRevu) | Funding Round | 0 |
6/2021 | Protenus | Series D | 0 |
6/2021 | TailorMed | Venture Round | 0 |
3/2021 | DexCare | Series A | 0 |
2/2021 | SpineZone | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|